March 1, 2017
Genticel, GenKyoTex to form Franco-Swiss NOX inhibitors focused Genkyotex
Euronext-listed Genticel and a privately-held Swiss GenKyoTex biopharmaceutical companies, will come together to become Genkyotex, a listed Franco-Swiss company whose focus will be develping a a pipeline of NOX inhibitors, a new therapeutic class in fibrosis and inflammatory pain.